title: A lipid microsphere vehicle for vinorelbine: Stability, safety and pharmacokinetics.
abstract: A lipid microsphere vehicle for vinorelbine (VRL) was designed to reduce the severe venous irritation caused by the aqueous intravenous formulation of VRL. Lipid microspheres (LMs) were prepared by high pressure homogenization. The physical stability was monitored by the appearance, particle size and zeta potential changes while the chemical stability was achieved by using effective antioxidants and monitored by long-term investigations. Safety tests were performed by testing rabbit ear vein irritation and a guinea pig hypersensitivity reaction. A pharmacokinetic study was performed by determining the drug levels in plasma up to 24h after intravenous administration of VRL-loaded LMs and conventional VRL aqueous injection separately. The VRL-loaded LMs had a particle size of 180.5+/-35.2nm with a 90% cumulative distribution less than 244.1nm, while the drug entrapment efficiency was 96.8%, and it remained stable for 12 months at 6+/-2 degrees C. The VRL-loaded LMs were less irritating and toxic than the conventional VRL aqueous injection. The pharmacokinetic profiles were similar and the values of AUC(0-t) were very close for the two formulations. A stable and easily mass-produced VRL-loaded LM preparation has been developed. It produces less venous irritation and is less toxic but has similar pharmacokinetics in vivo to the VRL aqueous injection currently commercially available.
authors: Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.
authors: Hong Yao
authors: HY
authors: Zhang
authors: Xing
authors: X
authors: Tang
authors: Hong Ying
authors: HY
authors: Li
authors: Xiao Liang
authors: XL
authors: Liu
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D019540:Area Under Curve; D004342:Drug Hypersensitivity / Q000209:etiology; D004355:Drug Stability; D004423:Ear / Q000098:blood supply; D004655:Emulsions; D006168:Guinea Pigs; D006863:Hydrogen-Ion Concentration; D007275:Injections, Intravenous; D054709:Lecithins / Q000737:chemistry; D008055:Lipids / Q000737:chemistry*; D008297:Male; D008863:Microspheres; D010316:Particle Size; D014677:Pharmaceutical Vehicles; D020442:Poloxamer / Q000737:chemistry; D011136:Polysorbates / Q000737:chemistry; D011312:Pressure; D011817:Rabbits; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000737:chemistry; D014680:Veins / Q000187:drug effects / Q000473:pathology; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics; D000077235:Vinorelbine
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004655:Emulsions; D054709:Lecithins; D008055:Lipids; D014677:Pharmaceutical Vehicles; D011136:Polysorbates; D014280:Triglycerides; D020442:Poloxamer; D014747:Vinblastine; D000077235:Vinorelbine